IL2 and myeloid sarcoma: Therefore, on the one hand, it may not be surprising that patients taking ocrelizumab display impaired antigen-specific T cell responses, where a significantly lower amount of IL-2 production by T cells in the MS cohort was observed (P = 0.013) when comparing patients that were infected with SARS-CoV-2 under ocrelizumab therapy (time point t2) with infected HCs.